Physician profile
William Johnson Taylor
NPI 1003886532
$1,902.29
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $336 · 2021: $251 · 2022: $556 · 2023: $536 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.91 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Antares Pharma, INC. | $167.26 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $154.56 | 2022-2023 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $153.42 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $102.36 | 2020-2023 | |
| Abiomed | $94.99 | 2024 | Impella |
| Glaxosmithkline, LLC. | $91.57 | 2020-2023 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $86.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $67.75 | 2019-2023 | Breztri |
| Pfizer INC. | $65.06 | 2020-2023 | |
| Amgen INC. | $52.36 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $45.27 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.82 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.23 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.61 | 2022-2023 | |
| Abbott Laboratories | $30.98 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $30.11 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $28.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.18 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $27.14 | 2019 | |
| Daiichi Sankyo INC. | $23.96 | 2022 | |
| Esperion Therapeutics, INC. | $19.65 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.02 | 2023 | Linzess |
| Astellas Pharma US INC | $17.84 | 2023 | Veozah |
| Bausch Health US, LLC | $15.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2022 | |
| Allergan, INC. | $14.34 | 2020 | |
| Novo Nordisk INC | $13.77 | 2022 | |
| Clarus Therapeutics INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.